Antibe Therapeutics (TSX:ATE) Pretax Margin % : % (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Antibe Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Antibe Therapeutics's Pre-Tax Income for the three months ended in Dec. 2023 was C$-4.21 Mil. Antibe Therapeutics's Revenue for the three months ended in Dec. 2023 was C$0.00 Mil. Therefore, Antibe Therapeutics's pretax margin for the quarter that ended in Dec. 2023 was %.

The historical rank and industry rank for Antibe Therapeutics's Pretax Margin % or its related term are showing as below:

TSX:ATE's Pretax Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -155.32
* Ranked among companies with meaningful Pretax Margin % only.

Antibe Therapeutics Pretax Margin % Historical Data

The historical data trend for Antibe Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antibe Therapeutics Pretax Margin % Chart

Antibe Therapeutics Annual Data

Trend

Mar14

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Pretax Margin %

Get a 7-Day Free Trial

-132.94

-197.08

Antibe Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pretax Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Antibe Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Antibe Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Antibe Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Antibe Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Antibe Therapeutics's Pretax Margin % falls into.

Antibe Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Antibe Therapeutics's Pretax Margin for the fiscal year that ended in Mar. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-19.291	/	0
	=	%

Antibe Therapeutics's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.213	/	0
	=	%

Antibe Therapeutics (TSX:ATE) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Antibe Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Antibe Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Antibe Therapeutics (TSX:ATE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Antibe Therapeutics Inc (TSX:ATE) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

ATBPF:USA

Address

15 Prince Arthur Avenue, Toronto, ON, CAN, M5R 1B2

Website

https://www.antibethera.com

Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.

Executives

Daniel Marcel Legault	Senior Officer
Alain Wilson	Senior Officer
John Lawrence Wallace	Director, Director or Senior Officer of 10% Security Holder, Senior Officer
Nicolas Bourgeois	Director or Senior Officer of Insider or Subsidiary (other than in 4,5,6)
Scott Wilson Curtis	Senior Officer

Antibe Therapeutics (TSX:ATE) Headlines

No Headlines